28 Feb 2011
A probiotic of the Bifidobacterium genus has been identified by Spanish researchers as being particularly effective in the treatment of ulcers. The strain B. bifidum CECT 7366 showed fantastic results from in vitro testing, exhibiting the inhibition of Helicobacter pylori - the main cause of many gastritis, gastric & duodenal ulcers - by up to 95%. The strains activity was further tested in mice with a 21 day trial revealing that mice given the probiotic strain developed significantly less ulcers than those who did not. The researchers concluded, "The results presented here confer to strain B. bifidum CECT 7366 the status of a probiotic bacterium with functional activity against H. pylori."
See the evidence for the Lacidofil formula also noted for its efficacy against H. pylori. For more information on the Bifidobacterium genus, take a look at the Probiotics Database here.
Reference: Chenoll, E. et al (2011). Novel Probiotic Bifidobacterium bifidum CECT 7366 Strain Active against the Pathogenic Bacterium Helicobacter pylori. Applied and Environmental Microbiology Journal, American Society for Microbiology, p. 1335-1343, Vol. 77, No. 4
Are you a health professional looking for research on probiotics?
These pages are intended for health professionals only.